295 related articles for article (PubMed ID: 20188100)
21. Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options.
Neumann H; Mönkemüller K; Vieth M; Malfertheiner P
Dig Dis; 2009; 27(1):18-23. PubMed ID: 19439956
[TBL] [Abstract][Full Text] [Related]
22. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728
[TBL] [Abstract][Full Text] [Related]
23. Current Status of Chemoprevention in Barrett's Esophagus.
Moayyedi P; El-Serag HB
Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
[TBL] [Abstract][Full Text] [Related]
24. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
Thrift AP; Anderson LA; Murray LJ; Cook MB; Shaheen NJ; Rubenstein JH; El-Serag HB; Vaughan TL; Schneider JL; Whiteman DC; Corley DA
Am J Gastroenterol; 2016 Nov; 111(11):1528-1535. PubMed ID: 27575711
[TBL] [Abstract][Full Text] [Related]
25. Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus.
Khalaf N; Nguyen T; Ramsey D; El-Serag HB
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1832-9.e6. PubMed ID: 24793026
[TBL] [Abstract][Full Text] [Related]
26. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
[TBL] [Abstract][Full Text] [Related]
27. Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?
Akın H; Aydın Y
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S31-S32. PubMed ID: 29199164
[TBL] [Abstract][Full Text] [Related]
28. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.
Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM
Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286
[TBL] [Abstract][Full Text] [Related]
29. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis.
Alexandre L; Clark AB; Bhutta HY; Holt S; Lewis MP; Hart AR
Gastroenterology; 2014 Mar; 146(3):661-8. PubMed ID: 24315828
[TBL] [Abstract][Full Text] [Related]
30. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C
Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852
[TBL] [Abstract][Full Text] [Related]
31. Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis.
Thrift AP
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2225-32. PubMed ID: 25835331
[TBL] [Abstract][Full Text] [Related]
32. Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.
Yao H; Wang L; Li H; Xu S; Bai Z; Wu Y; Chen H; Goyal H; Qi X
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):79-88. PubMed ID: 34806503
[TBL] [Abstract][Full Text] [Related]
33. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus.
Schneider JL; Zhao WK; Corley DA
Dig Dis Sci; 2015 Feb; 60(2):436-43. PubMed ID: 25213077
[TBL] [Abstract][Full Text] [Related]
34. Immortal person-time bias in relation to the use of nonsteroidal anti-inflammatory drugs and statins in the prevention of esophageal cancer in patients with Barrett's esophagus.
Azoulay L; Suissa S
Gastroenterology; 2012 May; 142(5):e20-1; author reply e21. PubMed ID: 22449575
[No Abstract] [Full Text] [Related]
35. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus.
Kantor ED; Onstad L; Blount PL; Reid BJ; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):456-61. PubMed ID: 22241250
[TBL] [Abstract][Full Text] [Related]
36. The Epidemiology of Esophageal Adenocarcinoma.
Coleman HG; Xie SH; Lagergren J
Gastroenterology; 2018 Jan; 154(2):390-405. PubMed ID: 28780073
[TBL] [Abstract][Full Text] [Related]
37. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Steyerberg EW; Biermann K; Valkhoff VE; Kuipers EJ; Bruno MJ;
Clin Gastroenterol Hepatol; 2013 Apr; 11(4):382-8. PubMed ID: 23200977
[TBL] [Abstract][Full Text] [Related]
38. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort.
Krishnamoorthi R; Borah B; Heien H; Das A; Chak A; Iyer PG
Gastrointest Endosc; 2016 Jul; 84(1):40-46.e7. PubMed ID: 26772891
[TBL] [Abstract][Full Text] [Related]
39. Chemoprevention in Barrett's esophagus: A pill a day?
Jankowski JA; Hooper PA
Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):155-70. PubMed ID: 21112505
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
